
|Videos|October 19, 2021
AMCP Nexus 2021: Jen Norton, VP & Head of U.S. Value & Access at Amgen Talks Biosimilar Trends and What to Expect in the Next Year
Jen Norton spoke at AMCP Nexus about biosimilar trends of 2021 and what to expect in the next 12 months
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves first treatment for chronic hepatitis D virus
2
Langlara, third interchangeable biosimilar to Lantus, approved by FDA
3
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
4
Family healthcare costs reach $37,824, analysis finds
5






















